Loading
Rezolute, Inc., a late-stage rare disease company, focused on improving outcomes for individuals with hypoglycemia caused by hyperinsulinism in the United States. Its lead clinical asset is ersodetug, an intravenously administered human monoclonal antibody that is in Phase 3 clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder, as well as for the treatment of hypoglycemia; and clinical trials of ersodetug for tumor hyperinsulinism. The company was formerly known as AntriaBio, Inc. and changed its name to Rezolute, Inc. in December 2017. Rezolute, Inc. was founded in 2010 and is headquartered in Redwood City, California.
Previous close
$4.87
+$0.23 · +4.96%
After-hours
$4.90
+$0.03 · +0.62%
Oct 9, 7:54 PM ET
Regular session · ET · Market data may be delayed.
Rezolute, Inc., a late-stage rare disease company, focused on improving outcomes for individuals with hypoglycemia caused by hyperinsulinism in the United States. Its lead clinical asset is ersodetug, an intravenously administered human monoclonal antibody that is in Phase 3 clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder, as well as for the treatment of hypoglycemia; and clinical trials of ersodetug for tumor hyperinsulinism. The company was formerly known as AntriaBio, Inc. and changed its name to Rezolute, Inc. in December 2017. Rezolute, Inc. was founded in 2010 and is headquartered in Redwood City, California.
Day range
Current $4.87
52-week range
Current $4.87
Regular session · ET · Market data may be delayed.
GoAI Score
Sell
Valuation
32
Expensive
Sentiment
65
Bullish
Risk
64
High Risk
Momentum
54
Neutral
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Rezolute, Inc., a late-stage rare disease company, focused on improving outcomes for individuals with hypoglycemia caused by hyperinsulinism in the United States. Its lead clinical asset is ersodetug, an intravenously administered human monoclonal antibody that is in Phase 3 clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder, as well as for the treatment of hypoglycemia; and clinical trials of ersodetug for tumor hyperinsulinism. The company was formerly known as AntriaBio, Inc. and changed its name to Rezolute, Inc. in December 2017. Rezolute, Inc. was founded in 2010 and is headquartered in Redwood City, California.
Day range
Current $4.87
52-week range
Current $4.87
Operating income
Net income
| Metric (USD) | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|---|
| Cost of goods sold | 31K USD | — | — | — | — |
| Gross profit | −31K USD | — | — | — | — |
| Research and development | 53.8M USD | 61.53M USD | 55.74M USD | 43.81M USD | 32.49M USD |
| Selling, general, and administrative | 29.17M USD | 18.37M USD | 14.68M USD | 12.18M USD | 9.36M USD |
| Operating expenses | 82.97M USD | 79.89M USD | 70.42M USD | 55.99M USD | 41.84M USD |
| Interest income | 4.88M USD | 5.48M USD | 4.87M USD | 4.21M USD | 80K USD |
| Interest expense | — | — | — | — | 1.81M USD |
| Depreciation and amortization | 31K USD | 31K USD | 36K USD | 30K USD | 13K USD |
| Operating income | −82.97M USD | −79.89M USD | −70.42M USD | −55.99M USD | −41.84M USD |
| Net income | −77.59M USD | −74.41M USD | −68.46M USD | −51.79M USD | −41.06M USD |
Company facts updated Oct 10, 2026.
Recent quarterly results
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Average target
$9.17
88.30% upside| Action | Effective date | Details | Record date | Payment date |
|---|---|---|---|---|
Stock split | Oct 13, 2020 | 1:50 | — | — |
Stock split | May 1, 2014 | 1:6 | — | — |
Effective Oct 13, 2020
1:50
Effective May 1, 2014
1:6
Funds reporting this stock among their holdings, ordered by reported position size.
Vanguard Morningstar Total Stock Market ETFVTI12.87M0.00%2.3T USD0.03%$381.94+0.63%
iShares Russell 2000 ETFIWM9.79M0.01%78.27B USD0.19%$278.94+0.49%
Vanguard Extended Market ETFVXF4.77M0.00%95.4B USD0.05%$235+0.80%
iShares Russell 2000 Value ETFIWN2.94M0.02%13.85B USD0.24%$210.87-0.04%
Dimensional - US Small Cap ETFDFAS2.21M0.01%33.87B USD0.31%$78.35+0.32%
Vanguard Russell 2000 ETFVTWO2.11M0.01%18B USD0.06%$112.66+0.50%
Schwab U.S. Small-Cap ETFSCHA1.9M0.01%21.73B USD0.03%$32.79+0.40%
Fidelity Enhanced Small Cap ETFFESM1.79M0.03%6.41B USD0.28%$45.46+0.46%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFiShares Russell 2000 Value ETFIWNDimensional - US Small Cap ETFDFASVanguard Russell 2000 ETFVTWOSchwab U.S. Small-Cap ETFSCHAFidelity Enhanced Small Cap ETFFESMAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
